Report of Foreign Issuer (6-k)
August 12 2020 - 08:46AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of the
Securities
Exchange Act of 1934
For
the month of August 2020
Commission
File Number: 001-36581
Vascular
Biogenics Ltd.
(Translation
of registrant’s name into English)
8
HaSatat St.,
Modi’in,
Israel
7178106
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F [X]
|
|
Form
40-F [ ]
|
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
______
EXPLANATORY
NOTE
On
August 12, 2020, Vascular Biogenics, Ltd. (the “Company”) issued a press release announcing the outcome of the second
interim analysis in its ongoing OVAL Phase 3 Ovarian Cancer Pivotal Study, a copy of which is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
This
report on Form 6-K and Exhibit 99.1 filed herewith hereto is being filed by the Company and is hereby expressly incorporated by
reference into the Company’s Registration Statements on Form F-3 (file nos. 333-222138 and 333-207250).
EXHIBITS
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
VASCULAR
BIOGENICS LTD.
|
|
|
|
Date:
August 12, 2020
|
By:
|
/s/
Dror Harats
|
|
Name:
|
Dror
Harats
|
|
Title:
|
Chief
Executive Officer
|
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2023 to Mar 2024